BioArctic Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

BioArctic hat ein Gesamteigenkapital von SEK992.7M und eine Gesamtverschuldung von SEK0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen SEK1.1B bzw. SEK143.6M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

kr0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	kr491.03m
Eigenkapital	kr992.73m
Gesamtverbindlichkeiten	kr143.61m
Gesamtvermögen	kr1.14b

Jüngste Berichte zur Finanzlage

Recent updates

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

Apr 13

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 19

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 03

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Dec 23

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Nov 12

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Jul 21

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Jul 15

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Jul 07

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

May 06

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Mar 13

Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher

Nov 30

We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn

Sep 16

We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow

Apr 04

We Think BioArctic (STO:BIOA B) Can Easily Afford To Drive Business Growth

Dec 05

BioArctic AB (publ) (STO:BIOA B) Shares Could Be 42% Below Their Intrinsic Value Estimate

Sep 15

BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business

Aug 23

Is BioArctic AB (publ) (STO:BIOA B) Trading At A 41% Discount?

Jun 03

Shareholders Will Probably Not Have Any Issues With BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation

Apr 29

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: BIOA BDie kurzfristigen Aktiva des Unternehmens (SEK1.1B) übersteigen seine kurzfristigen Passiva (SEK128.8M).

Langfristige Verbindlichkeiten: BIOA BDie kurzfristigen Vermögenswerte des Unternehmens (SEK1.1B) übersteigen seine langfristigen Verbindlichkeiten (SEK14.8M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: BIOA B ist schuldenfrei.

Schulden abbauen: BIOA B hat in den letzten 5 Jahren keine Schulden gemacht.

Schuldendeckung: BIOA B hat keine Schulden und muss daher nicht durch den operativen Cashflow gedeckt werden.

Zinsdeckung: BIOA B hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

BioArctic Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn

We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow

We Think BioArctic (STO:BIOA B) Can Easily Afford To Drive Business Growth

BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business

Recent updates

Insufficient new directors

Insider recently sold kr710k worth of stock

BioArctic AB (publ) Approves Leqembi [®] for the Treatment of Alzheimer's Disease in South Korea

First quarter 2024 earnings: Revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Consensus EPS estimates increase by 112%

Vice President of Human Resources exercised options to buy kr1.2m worth of stock.

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 15%

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Consensus revenue estimates fall by 16%

Consensus revenue estimates fall by 14%

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Independent Chairman recently bought kr1.1m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

VP & Head of Research recently sold kr2.8m worth of stock

VP & Head of Research exercised options to buy kr1.2m worth of stock.

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Consensus revenue estimates increase by 13%

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Consensus revenue estimates increase by 12%

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

Now 21% undervalued

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold kr6.5m worth of stock

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

Insider recently bought kr241k worth of stock

First quarter 2023 earnings released

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Independent Director recently sold kr3.3m worth of stock

Price target increased by 12% to kr400

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)

Consensus EPS estimates fall by 60%

Bioarctic AB's (Publ) Partner Eisai Announces that European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

BioArctic AB (publ) Announces Wenche Rolfsen Declines Re-Election to the Board

Consensus forecasts updated

BioArctic AB (publ) Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI for the Treatment of Alzheimer's Disease

Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher

Consensus forecasts updated

Bioarctic AB's (Publ) Partner Eisai Presents Results from lecanemab Confirmatory Phase 3 Clarity Ad Study

BioArctic AB (publ) Expands Portfolio with Alpha-Synuclein Brain Transporter Project

Insufficient new directors

BioArctic develops New treatment for Gaucher's Disease

Third quarter 2022 earnings released: EPS: kr1.55 (vs kr0.43 loss in 3Q 2021)

BioArctic AB (publ) to Report Q3, 2023 Results on Nov 08, 2023

BioArctic AB (publ), Annual General Meeting, Jun 01, 2023

Bioarctic Ab's (Publ) Announces Positive Topline Results for the Large Global Phase 3 Confirmatory Clarity Ad Study in 1,795 Subjects

We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn

Bioarctic AB (Publ) Announces Latest Data on Lecanemab Presented At Alzheimer's Association International Conference (Aaic)

Price target increased to kr266

Consensus estimates of losses per share improve by 35%

Second quarter 2022 earnings released: kr0.52 loss per share (vs kr0.39 loss in 2Q 2021)

Independent Deputy Chairman recently bought kr412k worth of stock

Insider recently bought kr100k worth of stock

First quarter 2022 earnings: Revenues miss analyst expectations

Price target increased to kr238

Insufficient new directors